Anatara Lifesciences gets good news on GaRP supplement
Anatara Lifesciences (ASX:ANR) has released encouraging pre-clinical trial data of its Gastrointestinal ReProgramming (GaRP) dietary supplement which targets diarrhoea. The company is now targeting the second half of this year for human trials of GaRP which treats underlying causes such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). “Anatara believes its GaRP dietary…